AMD hits multi-year highs on surprise Q2 profit >>> READ MORE

3 Biotech Stocks Where Momentum is Alive and Well

Take a swing for the fences with these three rising stars

      View All  

Regeneron Pharmaceuticals

REGN-LOGO.regeneronIf a relatively unknown bio-pharm stock with a narrow focus can soar 500%, imagine what a more diversified biotech stock with a pipeline of promising drugs can do for investors?

Regeneron (REGN) shares could see a big jump in 2014. The big promise in the year is with respect to expansion of its eye treatment product, Eylea. Analysts expect the company to grow profits by more than 50% in 2014. At current prices shares trade for 54 times 2014 estimated earnings. That’s a rich premium, but not nosebleed compared to some momentum stocks. The real potential for growth to be even larger than expected is what turns on the momentum ground and as other rocket ships come back to earth look for this one to keep on climbing.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC